SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00260520

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.

NCT00260520 Preeclampsia
MeSH: Pre-Eclampsia Fetal Growth Retardation
HPO: Intrauterine growth retardation Preeclampsia Toxemia of pregnancy

1 Interventions

Name: Dalteparin

Type: Drug



There is one SNP

SNPs


1 G20210A

Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation. --- G20210A ---

LMWH to Prevent Preeclampsia and Fetal Growth Restriction The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A ---

Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Inclusion Criteria: - Previous severe preeclampsia - Previous severe fetal growth restriction - Heterozygous Factor V Leiden - Heterozygous G20210A prothrombin gene mutations Exclusion Criteria: - renal disease - chronic hypertension - preexisting diabetes mellitus - homozygosity for Factor V Leiden - homozygosity for prothrombin G20210A mutation - hyperhomocysteinemia - protein C deficency - protein S deficency - antithrombin deficiency - positive anticardiolipin antibodies - positive lupus anticoagulant Preeclampsia Pre-Eclampsia Fetal Growth Retardation The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both. --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A --- --- G20210A ---



HPO Nodes


HPO:
Intrauterine growth retardation
Genes 398
CDKN1C SDHAF1 ASXL1 AARS CTU2 CCDC8 ERCC1 ERCC2 ABCB7 SF3B4 ERCC3 BRIP1 ERCC4 PDE4D ABL1 ERCC5 ERCC6 PDE6D ZMPSTE24 CEL PDGFB CENPE PDGFRB LEMD3 ORC6 DNAJC19 RBM10 SMC1A TRAIP TMEM216 ZFP57 DNAJC21 EVC DHDDS MCM4 LAGE3 MCM5 RPS19 WNT4 PCDH12 RREB1 ARID1A HNF4A TRIP13 CHRNA1 WARS2 ALX4 TUFM STN1 CHRND CHRNG HIRA RNU4ATAC CDC45 FANCA FANCC FANCD2 CITED2 FANCE ERCC8 FANCB FANCF FANCG ARID1B FBN1 ATRIP MBTPS2 SC5D COG1 COG6 HOXD13 FKTN PIK3R1 JAG1 RAB3GAP2 RECQL4 UFD1 PKLR EMG1 GTF2H5 KMT2A ALG8 FGF8 PLAGL1 NOP10 FGFR1 FGFR3 MAD2L2 TP53RK FTO SEC61A1 EIF2AK3 KDM6A NIPBL COG4 SDHA SDHB SDHD SLC25A24 FLI1 NDUFB11 TRAPPC11 FLNB KLF11 PSAT1 EXOSC9 TBX4 FMR1 DONSON NDUFAF5 AFF2 COMT TAPT1 RNASEH2A CTC1 PUF60 WHCR NSD2 NELFA IARS POLE WNT7A SMARCAL1 CEP290 SHH UQCC2 RFX6 CHD7 GATA5 SIN3A FLVCR2 OSGEP XRCC2 XRCC4 SIX3 FANCM NHP2 SKIV2L YY1 CDK10 ARCN1 CRKL ZIC2 TUBGCP6 RAB3GAP1 RAB18 NDUFAF4 IGF1 PIEZO2 IGF1R IGF2 FAM111A KANSL1 SEC24C UBE2T ARVCF DYNC2LI1 SLC20A2 OTUD6B TTC37 IGHMBP2 HHAT ZNF335 NUS1 DLL3 NUP133 SMARCA2 MPLKIP PRKAR1A SMARCA4 SMARCB1 SMARCC2 NKX2-5 APPL1 SMARCE1 CTBP1 MESP2 CEP152 PRKDC RERE MAPK1 CTNND2 FUT8 SUFU SNRPB GFM1 CEP57 MCTP2 PLK4 TRIM37 SIX2 SLX4 MUSK ATP5F1A UNC80 H19 SEMA3E SON UBR1 SOX11 ATP6V1A TCTN3 IBA57 ATP6V1E1 SAMD9 ATP7A CENPJ ATR WDR4 ACD RTEL1 INS MYOD1 RIPPLY2 RNF113A GAS1 INSR HDAC8 PTDSS1 CPLX1 GATA4 GATA6 PDX1 GBA FGFRL1 NBN NKX2-6 GCK QRICH1 PIGG PSPH CUL7 NDUFA6 TUBGCP4 SRCAP PTCH1 GDF1 NDUFA10 COQ2 BCR NDUFB3 GPKOW NSUN2 BCS1L NEK9 GINS1 PHGDH STAT3 MKS1 ITPA TBC1D20 NSDHL DDX11 BLK BLM XYLT1 IFIH1 GJA5 SEC24D FAM20C PTPN11 ARL6IP6 NEUROD1 BRCA1 BRAF BRCA2 TINF2 KLHL7 FIG4 WASHC5 GLI1 GLI2 GLI3 ABCC8 DHCR7 DHCR24 BRPF1 KCNJ11 TMEM70 COQ9 HES7 BUB1 BUB1B PEX2 PEX5 PYCR1 HYLS1 DKC1 KIF14 ALDH18A1 KIF2A CDT1 KIF5C TAF1 BMPER STRA6 FOXH1 GTPBP3 HYMAI NODAL TALDO1 TBX1 ALG1 CDON TBCE GP1BB RAD21 TBX6 RAD51 RAD51C SFXN4 RAF1 HNF1A PDSS2 EVC2 B3GLCT PLOD3 RAPSN RARB HDAC6 NUP107 USB1 RB1 SLC26A2 COG7 RBBP8 DOK7 TPRKB NUP88 GLIS3 DYRK1A OBSL1 SEMA5A FANCL RIPK4 TDGF1 DPF2 WRAP53 DLL1 CCNQ LARS2 TERC TERT TFAM TFAP2A GMNN JMJD1C PALB2 LETM1 LFNG TSFM ZFPM2 RFWD3 POLR3A STT3B ADGRG6 ESCO2 TTC7A ORC1 ORC4 LIFR TGIF1 MLXIPL LIG4 GTF2E2 BCAP31 HMGA2 LMNA SMC3 CDCA7 SETD5 P4HB COQ4 FANCI ARID2 PPP1R15B TGDS PAH CTDP1 CKAP2L WDR73 PARN ELN PAX4 HADH CDC6 BUB3 DISP1 VPS13B TOP3A COQ7 RPL10 RPL11 SMAD4 ATP6V0A2 PCNT XPR1 NIN
Preeclampsia
Genes 15
HBA2 CFI CFH F5 CORIN CYP11B1 CYP11B2 EP300 CD46 SLC25A20 LBR HELLPAR STOX1 PPARG HBA1
Toxemia of pregnancy
Genes 17
HBA2 LMNA CFI CFH F5 CORIN CYP11B1 CYP11B2 EP300 NR3C2 CD46 SLC25A20 LBR HELLPAR STOX1 PPARG HBA1